The total return for Stryker Corporation (SYK) stock is -16.86% over the past 12 months vs. +25.95% for the S&P 500. So far it's up -11.40% this year. Includes price appreciation + reinvested dividends.
Stryker Corporation (SYK) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (17.66%) | +1.80% | +3.91% | +10.48% | +11.84% | +10.13% |
| Total Return CAGR | (16.86%) | +2.79% | +4.98% | +11.71% | +13.24% | +11.38% |
| Revenue CAGR | +8.84% | +10.06% | +11.42% | +9.65% | +8.40% | +8.45% |
| Net Income CAGR | +16.72% | +8.30% | +18.84% | +7.51% | +6.72% | +8.68% |
| EPS CAGR | +8.02% | +10.87% | +14.79% | +8.31% | +6.70% | +8.70% |
| Free Cash Flow CAGR | +27.79% | +26.33% | +11.01% | +28.14% | +8.90% | +10.93% |
| Operating Cash Flow CAGR | +25.35% | +23.31% | +11.37% | +22.24% | +8.99% | +9.64% |
| Dividends CAGR | (48.26%) | (16.74%) | (7.40%) | +1.18% | +5.83% | +10.96% |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
SYK Total Return CAGR Chart
Stryker Corporation (SYK)
Annual Total Returns Comparison
| Year | Start Value | End Value | SYK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 7049.07 | 6245.66 | (11.40%) | +10.34% | (21.74%) |
| 2025 | 7155.41 | 7049.07 | (1.49%) | +17.72% | (19.21%) |
| 2024 | 5897.26 | 7155.41 | +21.33% | +24.89% | (3.56%) |
| 2023 | 4764.16 | 5897.26 | +23.78% | +26.19% | (2.41%) |
| 2022 | 5146.32 | 4764.16 | (7.43%) | (18.17%) | +10.74% |
| 2021 | 4669.10 | 5146.32 | +10.22% | +28.74% | (18.52%) |
| 2020 | 3951.94 | 4669.10 | +18.15% | +18.37% | (0.22%) |
| 2019 | 2920.17 | 3951.94 | +35.33% | +31.22% | +4.11% |
| 2018 | 2850.80 | 2920.17 | +2.43% | (4.56%) | +6.99% |
| 2017 | 2178.90 | 2850.80 | +30.84% | +21.70% | +9.14% |
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo